申请人:Mazitschek Ralph
公开号:US20120208889A1
公开(公告)日:2012-08-16
HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase/deacetylase activity as described herein (e.g., cancer). In certain embodiments, the compounds of the invention selectively target either a class or isoform of the HDAC family. Another aspect of the invention provides an assay for determining the inhibitory effect of a test compound on an HDAC protein comprising: incubating the HDAC protein with a substrate of general formula (IIIc) in the presence of a test compound; and determining the activity of the HDAC protein.
本文描述的具有一般式(I)和(II)及其药学上可接受的盐的HDAC抑制剂,可用作组蛋白去乙酰化酶或其他去乙酰化酶的抑制剂,并因此可用于治疗与去乙酰化酶/乙酰化酶活性相关的各种疾病和疾病,如本文所述(例如癌症)。在某些实施例中,本发明的化合物有选择性地靶向HDAC家族的一类或同工酶。本发明的另一个方面提供了一种测定试验化合物对HDAC蛋白质抑制作用的测定方法,包括:在试验化合物的存在下,将HDAC蛋白质与一般式(IIIc)的底物孵育,并确定HDAC蛋白质的活性。